373110.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.81, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing.

Profitability metrics show a challenging financial performance, with a return on equity of -1.53 and a return on assets of -0.695, both significantly below the industry median for pharmaceutical companies. The company reported a gross loss of KRW 1,954,692,440 and an operating loss of KRW 10,851,766,660, indicating a lack of operational efficiency and cost control. These figures suggest the company is not generating sufficient revenue to cover its costs and is not currently profitable.

The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of its revenue streams. However, the absence of detailed segment reporting may indicate a lack of diversification or a focus on a single core business line, which could expose the company to higher risk if that line underperforms.

Looking at the company's growth trajectory, the available data does not provide specific outlook figures for the current or next fiscal year. The company's historical financial performance, marked by declining profitability and negative cash flows, suggests a lack of growth momentum. The operating cash flow of -KRW 9,502,028,780 and free cash flow of -KRW 10,406,217,310 indicate that the company is not generating positive cash from operations and is likely relying on external financing to sustain its operations.

The company's risk profile is elevated due to its negative net cash position and significant operating losses. The risk assessment indicates a medium liquidity risk, which could become more severe if the company is unable to secure additional financing or improve its cash flow generation. The dilution risk is assessed as low, but the company's capital structure and financial performance suggest that it may need to issue additional shares in the future to raise capital, which could dilute existing shareholders' equity.

Recent events and filings do not provide specific details about the company's strategic initiatives or operational changes. However, the company's financial performance and liquidity position suggest that it may be undergoing a period of financial stress or restructuring. The absence of positive financial trends and the presence of significant operating losses indicate that the company may need to take corrective actions to stabilize its financial position.